EPA:ALQGC - Euronext Paris - Matif - FR0011648971 - Common Stock - Currency: EUR
EPA:ALQGC (10/24/2024, 7:00:00 PM)
0.0721
0 (-1.77%)
The current stock price of ALQGC.PA is 0.0721 EUR. In the past month the price increased by 175.19%. In the past year, price decreased by -23.78%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20.53 | 343.18B | ||
1ABBV.MI | ABBVIE INC | 20.51 | 342.83B | ||
AMG.DE | AMGEN INC | 15.79 | 157.07B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.31 | 135.91B | ||
GIS.DE | GILEAD SCIENCES INC | 24.78 | 133.10B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1674.07 | 116.12B | ||
ARGX.BR | ARGENX SE | 259.28 | 35.13B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.96B | ||
IDP.DE | BIOGEN INC | 8.67 | 19.45B | ||
0QF.DE | MODERNA INC | N/A | 12.31B | ||
1MRNA.MI | MODERNA INC | N/A | 12.31B | ||
GLPG.AS | GALAPAGOS NV | 7.87 | 1.62B |
Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
QUANTUM GENOMICS SAS-REGR
33 rue Marbeuf
Paris ILE-DE-FRANCE FR
Employees: 3
Company Website: https://quantum-genomics.com/
Phone: 33185347770
The current stock price of ALQGC.PA is 0.0721 EUR. The price decreased by -1.77% in the last trading session.
The exchange symbol of QUANTUM GENOMICS SAS-REGR is ALQGC and it is listed on the Euronext Paris - Matif exchange.
ALQGC.PA stock is listed on the Euronext Paris - Matif exchange.
7 analysts have analysed ALQGC.PA and the average price target is 10.2 EUR. This implies a price increase of 14047.02% is expected in the next year compared to the current price of 0.0721. Check the QUANTUM GENOMICS SAS-REGR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUANTUM GENOMICS SAS-REGR (ALQGC.PA) has a market capitalization of 5.00M EUR. This makes ALQGC.PA a Nano Cap stock.
QUANTUM GENOMICS SAS-REGR (ALQGC.PA) currently has 3 employees.
QUANTUM GENOMICS SAS-REGR (ALQGC.PA) has a support level at 0.06 and a resistance level at 0.08. Check the full technical report for a detailed analysis of ALQGC.PA support and resistance levels.
The Revenue of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) is expected to grow by 1744.53% in the next year. Check the estimates tab for more information on the ALQGC.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALQGC.PA does not pay a dividend.
QUANTUM GENOMICS SAS-REGR (ALQGC.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
ChartMill assigns a technical rating of 4 / 10 to ALQGC.PA. When comparing the yearly performance of all stocks, ALQGC.PA is a bad performer in the overall market: 93.91% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to ALQGC.PA. Both the profitability and financial health of ALQGC.PA have multiple concerns.
Over the last trailing twelve months ALQGC.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 87.28% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -84.63% | ||
ROE | -726.18% | ||
Debt/Equity | 4.49 |
ChartMill assigns a Buy % Consensus number of 34% to ALQGC.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 6121.43% and a revenue growth 1744.53% for ALQGC.PA